Boehringer Ingelheim opens US R&D site

23 January 2001

Boehringer Ingelheim of Germany has opened a new R&D site at its USheadquarters in Ridgefield, Connecticut. The 30,000-square-foot facility contains what the firm describes as "highly-sophisticated equipment designed to accelerate the screening and discovery of chemical compounds."

Andreas Barner, a member of BI's board of managing directors, said that the new unit "will mark a crucial milestone" in the company's history, as it implements its strategy of expanding R&D in the USA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight